依达拉奉治疗急性心肌梗塞的疗效观察

目的：观察依达拉奉治疗急性心肌梗塞（AMI）的疗效。方法：60例发病48h内行溶栓或经皮冠状动脉介入治疗（PCI）后的心肌梗塞患者被随机分为对照组（32例）、依达拉奉组（28例），治疗2～3周后比较疗效。结果：与对照组相比，依达拉奉组患者左室射血分数（LVEF）明显升高[51．9±4．99）％：（55．31±5．36）％，P〈0．05]，住院期间恶性心律失常发生率明显降低（25．9％：13．3％，P〈0．05），但两组患者住院期间总体病死率无明显差异（P〉0．05）。结论：依达拉奉作为一种新型氧自由基清除剂，治疗急性心肌梗塞有明显的疗效。

Therapeutic effect of edaravone on acute myocardial infarction

Objective： To observe the efficacy of edaravone on acute myocardial infarction （AMI）. Methods： Sixty AMI patients in 48 h and after treatment of thrombolysis or PCI were randomly divided into 2 groups： Routine therapy control group （n= 30） and edaravone group （n= 28）, the efficacy was assessed between two groups 2-3 weeks after treatment. Results： Compared with control group, the level of LVEF significantly increased [51.9 ± 4.99）% vs. （55.31 ± 5.36）%, P〈0.05], and the incidence of malignant arrhythmia decreased dramatically （25.9% vs. 13.3% , P〈0.05）, but there was no significant difference in fatality rate between two groups （P〉0.05）. Conclusion： As a new hydro--free radical scavenger, edaravone has obvious effects on acute myocardial infarction.